MedTrace Logo

LIPT - Liraglutide in Polycystic Ovary Syndrome

NCT02073929 · Status: COMPLETED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 72

Last updated 2019-02-28

Study results available
· View outcomes & findings →

Summary

Polycystic ovary syndrome (PCOS) affects 5-10% of women in fertile age. PCOS is associated with metabolic syndrom, diabetes and and increased risk og cardiovascular disease.

The study investigates the effect af intervention with GLP-1-analog on risk markers of cardiovascular disease in women with PCOS.

70 women will be included in af RCT.

Hypothesis: GLP-1-analog treatment in women with PCOS (without diabetes) will result in a beneficial reduction in risk markers of vascular thrombosis and early cardiovascular disease.

Conditions

Interventions

DRUG

Liraglutide for 26 weeks

GLP-1-analogue Liraglutide s.c. 1,8mg daily for 26 weeks

DRUG

placebo

Placebo s.c. daily for 26 weeks

Sponsors & Collaborators

  • Jens Faber

    lead OTHER

Principal Investigators

  • Jens Faber, DSc · Dept. of Medicine, Herlev Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
60 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-03-31
Primary Completion
2015-12-31
Completion
2015-12-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02073929 on ClinicalTrials.gov